It is still in high demand to develop extremely sensitive and accurate clinical tools for biomarkers of interest for early diagnosis and monitoring of diseases. In this report, we present a highly sensitive and compatible gold nanoparticle (AuNP)-based fluorescence activatable probe for sensing ultra-low levels of prostate-specific antigen (PSA) in patient serum samples. The limit of detection of the newly-developed probe for PSA was pushed down to 0.032 pg/mL, which is more than two orders of magnitude lower than that of the conventional fluorescence probe. The ultrahigh sensitivity of this probe was attributed to the high loading efficiency of the dyes on AuNP surfaces and high fluorescence quenching unquenching abilities of the dye-AuNP pairs. The efficiency and robustness of this probe was investigated in patient serum samples, demonstrating the great potential of this probe in real-world applications.
Keywordsfluorescence activatable probe; gold nanoparticle; prostate specific antigen (PSA); Rhodamine B isothiocyanate (RBITC)We report a fluorescence-based activatable immunoassay for ultrasensitive detection of cancer biomarkers in a panel of serum samples. A biomarker is defined as the "molecular signature" of a physiological or disease process at certain stages and is therefore particularly useful for diagnosing disease, monitoring disease progression and evaluating therapeutic response. 1,2 Many diseases such as cancers are much more susceptible to treatment when diagnosed in the early stages, indicating that earlier diagnosis of the disease may enable improved therapeutic intervention. 3 However, the levels of biomarkers are often low in * To whom correspondence should be addressed. Xiaoyuan Chen (shawn.chen@nih.gov).
Supporting InformationDetails of characterizing gold nanoparticles and various conjugates described here can be found in the Supporting Information. This material is available free of charge via the Internet at http://pubs.acs.org.The authors declare no competing financial interest.
NIH Public AccessAuthor Manuscript ACS Nano. Author manuscript; available in PMC 2014 June 25.Published in final edited form as: ACS Nano. 2013 June 25; 7(6): 5568-5576. doi:10.1021/nn401837q.
NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript biological samples from patients. 4,5 It is therefore extremely important to develop ultrasensitive biosensors for biomarkers of interest.The current gold standard for clinical biomarker detection is the enzyme-linked immunosorbent assay (ELISA). However, due to its moderate sensitivity, ELISA usually allows detection only after biomarker levels have already reached critical threshold concentrations, at which point the disease has already advanced remarkably. Thus, ultrasensitive assays are urgently required for detection of biomarkers in the clinic. Nanotechnology is already playing an increasingly important role in the design of ultrasensitive biosensors. 68 In the past few decades, many efforts have been made to create signal transducers ...